Longstanding and Refractory Anti-Muscle Specific Tyrosine Kinase Antibody-Associated Myasthenia Gravis (Anti-MuSK-MG) in a Child Successfully Treated with Rituximab
| Autor: | Steven Weger, Ian Clark, Juan Pablo Appendino |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.drug_class
Monoclonal antibody Refractory immune system diseases hemic and lymphatic diseases Myasthenia Gravis medicine Humans Immunologic Factors Receptors Cholinergic Child Autoantibodies CD20 biology Electromyography business.industry Remission Induction Receptor Protein-Tyrosine Kinases medicine.disease Myasthenia gravis Ophthalmology Pediatric patient Immunology biology.protein Female Rituximab Antibody business Tyrosine kinase medicine.drug |
| Zdroj: | Journal of Binocular Vision and Ocular Motility. 69:26-29 |
| ISSN: | 2576-1218 2576-117X |
| Popis: | Anti-muscle specific tyrosine kinase antibody-associated myasthenia gravis (MuSK-MG) is a rare subtype of MG characterized by more frequent relapses and a clinical course that is refractory to standard treatments. Rituximab, a monoclonal antibody targeting CD20+ B cells, has been used effectively in the adult population to achieve stable remission. We describe a pediatric patient with MuSK-MG who demonstrated an excellent response to rituximab after failing standard therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|